



22 May 2014
EMA/CHMP/312178/2014
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Arzerra

ofatumumab

On 22 May 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Arzerra. The marketing authorisation holder for this medicinal product is Glaxo Group Ltd. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication as follows:

"Previously untreated chronic lymphocytic leukaemia (CLL):

Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.

See section 5.1 for further information."

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

For information, the full indications for Arzerra will be as follows²:

Previously untreated chronic lymphocytic leukaemia (CLL):

Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.

See section 5.1 for further information.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

² The text in bold represents the new or the amended indication.



Refractory CLL:

Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.

See section 5.1 for further information.